STOCK TITAN

Vanda Pharmaceuticals to Announce Third Quarter 2023 Financial Results on November 8, 2023

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) will release its third quarter 2023 results on November 8, 2023, after the market closes. The company will host a conference call at 4:30 PM ET on the same day to discuss the financial results and other corporate activities. The call can be accessed by dialing 1-800-715-9871 (domestic) or 1-646-307-1963 (international) with passcode 9774278. The call will also be broadcasted and archived on Vanda's website. A replay of the call will be available until November 15, 2023, with the call-in numbers 1-800-770-2030 (domestic) and 1-609-800-9909 (international) with passcode 9774278.
Positive
  • None.
Negative
  • None.

Conference Call and Webcast to Follow

WASHINGTON, Nov. 1, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2023 on Wednesday, November 8, 2023, after the market closes.  

Vanda will host a conference call at 4:30 PM ET on Wednesday, November 8, 2023, during which management will discuss the third quarter 2023 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 9774278.

The conference call will be broadcast simultaneously and archived on Vanda's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Wednesday, November 8, 2023, beginning at 8:30 PM ET and will be accessible until Wednesday, November 15, 2023, at 8:30 PM ET. The replay call-in number is 1-800-770-2030 for domestic callers and 1-609-800-9909 for international callers. The passcode number is 9774278.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer 
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-to-announce-third-quarter-2023-financial-results-on-november-8-2023-301974881.html

SOURCE Vanda Pharmaceuticals Inc.

FAQ

When will Vanda Pharmaceuticals release its third quarter 2023 results?

Vanda Pharmaceuticals will release its third quarter 2023 results on November 8, 2023, after the market closes.

What is the date and time of the conference call to discuss the financial results?

The conference call to discuss the financial results will take place on November 8, 2023, at 4:30 PM ET.

How can I participate in the conference call?

To participate in the conference call, dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) with passcode 9774278.

Where can I access the conference call recording?

The conference call will be broadcasted and archived on Vanda's website, www.vandapharma.com.

How long will the replay of the call be available?

The replay of the call will be available until November 15, 2023.

What are the call-in numbers for the replay?

The call-in numbers for the replay are 1-800-770-2030 (domestic) and 1-609-800-9909 (international) with passcode 9774278.

Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

VNDA Rankings

VNDA Latest News

VNDA Stock Data

285.75M
52.05M
5.21%
91.5%
4.32%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
WASHINGTON

About VNDA

vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.